| Name | Title | Contact Details |
|---|---|---|
Max Goodman |
Director of Information Technology | Profile |
Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.
Novus Anesthesia Partners is a company that provides anesthesia management services for small to medium size hospitals, solving financial and operational challenges in the delivery of anesthesia services.
Ovia Health is a family health benefits platform helping women and families with personalized and data-driven solutions for fertility, pregnancy, and parenting.
ProviderLink is a Cary, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MGC Diagnostics Corporation is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.